Abstract

Background/Aim: High-mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is expressed in many human neoplasms. Oral squamous cell carcinoma (OSCC) is one of the leading cancers in the world, particularly in Southeast Asia. In this study, the expression level of HMGA2 was determined on tissue microarray of OSCC and its correlation with prognosis of patients was studied. Materials and Methods: Immunohistochemistry of HMGA2 was analyzed on resection samples from 148 patients with OSCC. The expression level of HMGA2 was determined by ImmunoRatio. Results: High expression of HMGA2 in OSCC was found to be associated with tumor recurrence (p=0.026). Cox model analysis revealed that high expression of HMGA2 was significantly associated with poor survival in patients with OSCC. The Kaplan-Meier analysis also showed decreased survival in patients with high HMGA2 expression. By combining HMGA2 immunostaining and clinicopathological characteristics as analyzing factors, high HMGA2 expression was specifically correlated with poor survival in patients with perineural invasion and lymph node metastasis of OSCC. Additionally, high expression of HMGA2 was found to be a tumor-stage independent prognostic factor associated with high incidence of tumor recurrence and shortened recurrence-free survival. Conclusion: HMGA2 is not only a biomarker forpredicting patients with tumor recurrence and poor survival, but when combined with clinicopathological factors, can categorize patients into different risk groups for better clinical management of OSCC.

Original languageEnglish
Pages (from-to)1891-1899
Number of pages9
JournalAnticancer Research
Volume37
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

AT-Hook Motifs
Squamous Cell Carcinoma
Recurrence
Survival
Neoplasms
Southeastern Asia
Kaplan-Meier Estimate
Proportional Hazards Models

Keywords

  • HMGA2
  • Lymph node metastasis
  • Oral squamous cell carcinoma
  • Perineural invasion
  • Prognosis
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{4afd87e467694ef6833c09f2e9358f45,
title = "High HMGA2 expression correlates with reduced recurrence-free survival and poor overall survival in oral squamous cell carcinoma",
abstract = "Background/Aim: High-mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is expressed in many human neoplasms. Oral squamous cell carcinoma (OSCC) is one of the leading cancers in the world, particularly in Southeast Asia. In this study, the expression level of HMGA2 was determined on tissue microarray of OSCC and its correlation with prognosis of patients was studied. Materials and Methods: Immunohistochemistry of HMGA2 was analyzed on resection samples from 148 patients with OSCC. The expression level of HMGA2 was determined by ImmunoRatio. Results: High expression of HMGA2 in OSCC was found to be associated with tumor recurrence (p=0.026). Cox model analysis revealed that high expression of HMGA2 was significantly associated with poor survival in patients with OSCC. The Kaplan-Meier analysis also showed decreased survival in patients with high HMGA2 expression. By combining HMGA2 immunostaining and clinicopathological characteristics as analyzing factors, high HMGA2 expression was specifically correlated with poor survival in patients with perineural invasion and lymph node metastasis of OSCC. Additionally, high expression of HMGA2 was found to be a tumor-stage independent prognostic factor associated with high incidence of tumor recurrence and shortened recurrence-free survival. Conclusion: HMGA2 is not only a biomarker forpredicting patients with tumor recurrence and poor survival, but when combined with clinicopathological factors, can categorize patients into different risk groups for better clinical management of OSCC.",
keywords = "HMGA2, Lymph node metastasis, Oral squamous cell carcinoma, Perineural invasion, Prognosis, Recurrence",
author = "Fang, {Chih Yeu} and Liew, {Phui Ly} and Chen, {Chi Long} and Lin, {Yun Ho} and Fang, {Chia Lang} and Chen, {Wei Yu}",
year = "2017",
month = "4",
day = "1",
doi = "10.21873/anticanres.11527",
language = "English",
volume = "37",
pages = "1891--1899",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - High HMGA2 expression correlates with reduced recurrence-free survival and poor overall survival in oral squamous cell carcinoma

AU - Fang, Chih Yeu

AU - Liew, Phui Ly

AU - Chen, Chi Long

AU - Lin, Yun Ho

AU - Fang, Chia Lang

AU - Chen, Wei Yu

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background/Aim: High-mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is expressed in many human neoplasms. Oral squamous cell carcinoma (OSCC) is one of the leading cancers in the world, particularly in Southeast Asia. In this study, the expression level of HMGA2 was determined on tissue microarray of OSCC and its correlation with prognosis of patients was studied. Materials and Methods: Immunohistochemistry of HMGA2 was analyzed on resection samples from 148 patients with OSCC. The expression level of HMGA2 was determined by ImmunoRatio. Results: High expression of HMGA2 in OSCC was found to be associated with tumor recurrence (p=0.026). Cox model analysis revealed that high expression of HMGA2 was significantly associated with poor survival in patients with OSCC. The Kaplan-Meier analysis also showed decreased survival in patients with high HMGA2 expression. By combining HMGA2 immunostaining and clinicopathological characteristics as analyzing factors, high HMGA2 expression was specifically correlated with poor survival in patients with perineural invasion and lymph node metastasis of OSCC. Additionally, high expression of HMGA2 was found to be a tumor-stage independent prognostic factor associated with high incidence of tumor recurrence and shortened recurrence-free survival. Conclusion: HMGA2 is not only a biomarker forpredicting patients with tumor recurrence and poor survival, but when combined with clinicopathological factors, can categorize patients into different risk groups for better clinical management of OSCC.

AB - Background/Aim: High-mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is expressed in many human neoplasms. Oral squamous cell carcinoma (OSCC) is one of the leading cancers in the world, particularly in Southeast Asia. In this study, the expression level of HMGA2 was determined on tissue microarray of OSCC and its correlation with prognosis of patients was studied. Materials and Methods: Immunohistochemistry of HMGA2 was analyzed on resection samples from 148 patients with OSCC. The expression level of HMGA2 was determined by ImmunoRatio. Results: High expression of HMGA2 in OSCC was found to be associated with tumor recurrence (p=0.026). Cox model analysis revealed that high expression of HMGA2 was significantly associated with poor survival in patients with OSCC. The Kaplan-Meier analysis also showed decreased survival in patients with high HMGA2 expression. By combining HMGA2 immunostaining and clinicopathological characteristics as analyzing factors, high HMGA2 expression was specifically correlated with poor survival in patients with perineural invasion and lymph node metastasis of OSCC. Additionally, high expression of HMGA2 was found to be a tumor-stage independent prognostic factor associated with high incidence of tumor recurrence and shortened recurrence-free survival. Conclusion: HMGA2 is not only a biomarker forpredicting patients with tumor recurrence and poor survival, but when combined with clinicopathological factors, can categorize patients into different risk groups for better clinical management of OSCC.

KW - HMGA2

KW - Lymph node metastasis

KW - Oral squamous cell carcinoma

KW - Perineural invasion

KW - Prognosis

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=85017472772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017472772&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11527

DO - 10.21873/anticanres.11527

M3 - Article

C2 - 28373457

AN - SCOPUS:85017472772

VL - 37

SP - 1891

EP - 1899

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -